BACKGROUND AND OBJECTIVES: Neurolytic superior hypogastric @entity616 has been shown to be safe and effective in selected @entity5 @entity1 . A large cohort of @entity1 was studied to evaluate the continued efficacy and safety of this block in @entity5 @entity1 with @entity1442 . METHODS: A total of 227 @entity2371 @entity1 with gynecological, @entity14 who experienced poor @entity158 control due to either @entity74 or to untoward side effects were enrolled in this study during a 3-year period. All @entity158 @entity1 receiving oral opioids were eligible to participate. A bilateral percutaneous neurolytic superior hypogastric @entity616 with 10% @entity3971 was performed 1 day after a successful diagnostic block with 0.25% @entity1341 . RESULTS: All @entity1 reported a visual analog scale (VAS) @entity158 score of 7-10/10 before the block. A positive response to a diagnostic block was obtained in 159 @entity1 (79%). Overall, 115 @entity1 of the 159 @entity1 who responded to a diagnostic block (72%, 95% confidence interval of 65-79%) had @entity158 relief (VAS < 4/10), 99 (62%) after one block, and 16 (10%) after a second block. The remaining 44 @entity1 (28%) had moderate @entity158 control (VAS 4-7/10) after two blocks and received oral pharmacological therapy and epidural analgesic therapy with good results. Both groups experienced significant reductions in oral opioid therapy after the @entity616 . No additional blocks were required by @entity1 who had a good response during a follow-up period of 3 months. No complications related to the block were detected. CONCLUSIONS: Neurolytic superior hypogastric @entity616 provided both effective @entity158 relief and a significant reduction in opioid usage (43%) in 72% of the @entity1 who received a @entity616 . Overall, this represents 51% of the @entity1 enrolled in the study. Poor results should be expected in @entity1 with extensive @entity66 overlying the plexus because of inadequate spread of the neurolytic agent.

Neurolytic superior hypogastric @entity616 for chronic @entity2371 associated with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity66 :: ('MESH:D004194', 'Disease') :: ['retroperitoneal disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity2371 :: ('MESH:D017699', 'Disease') :: ['pelvic pain'] @entity3971 :: ('MESH:D019800', 'Chemical') :: ['phenol'] @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity74 :: ('MESH:D030342', 'Disease') :: ['progression of disease'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal, or genitourinary cancer'] @entity158 :: ('MESH:D010146', 'Disease') :: ['satisfactory pain', 'pain'] @entity616 :: ('MESH:D006327', 'Disease') :: ['plexus block', 'neurolytic block', 'neurolytic blocks']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
